

Invited Speakers
CIRM Loan Task Force Meeting
December 9, 2009

Gregory Bonfiglio
Managing Partner, Proteus Venture Partners

Gregory A. Bonfiglio is the Managing Partner of Proteus Venture Partners - a new venture fund that will focus solely on stem cell & regenerative medicine companies. He is in the process of raising the investment capital for that Fund, and is seeking new stem cell & regenerative medicine investment opportunities. Greg was an early investor in stem cell & regenerative medicine companies - his prior firm, Anthem Venture Partners, funded Advanced Cell Technology (ACTC.OB) in 2000, and Mr. Bonfiglio led the team that took the Company public in early 2005.

Mr. Bonfiglio continues to be an active participant in the field of Regenerative Medicines. He is a frequent speaker at Regenerative Medicine Conferences. He is a Member of the ISSCR and is on their Industry Committee. He also is a Member of the ISCT and is on their Commercialization Committee. Mr. Bonfiglio is on the Board of VistaGen Therapeutics.

From 2000 - 2005, Greg was a General Partner with Anthem Venture Partners - a diversified early stage venture fund in California, with returns in the Top 5% of all 2000 funds. Prior to joining Anthem, he was a Partner with Morrison & Foerster, where he worked extensively with technology clients. From 1996 to 2000, Mr. Bonfiglio was an Adjunct Professor of Law at Stanford Law School. Since 1995, he has been a regular Guest Lecturer at the UC Berkley Haas Business School.

Bruce Cohen
President & CEO and Founder, VitaPath Genetics, Inc.

Bruce Cohen has spent more than 25 years in leadership positions in life science and high technology companies. He was the founding President and CEO of two early stage biotechnology companies: Cellerant Therapeutics and Acacia BioSciences. He also served as Chief Financial Officer for GeneSoft Pharmaceuticals prior to its merger into Oscient Pharmaceuticals. In addition, he held senior positions in business development and marketing at SEQUUS Pharmaceuticals and Baxter. Mr. Cohen was the President and COO of ViTel International, a privately held, pre-internet electronic messaging company and was a management consultant with Monitor Company working in the health care and high technology sectors.

Mr. Cohen has an MBA, with distinction, from Harvard Business School, and a BA and MA from Tufts University. He was one of the founders of the Tufts Veterinary School and a co-founder of the Health Professions Information Bureau.

Bryant Fong
Managing Director, Burrill & Company

Bryant Fong joined Burrill & Company in 1998 and has been focused on sourcing, evaluating and investing in biotechnology companies through the Burrill Life Sciences Capital Funds, which combined total almost \$1 billion for investments in the life sciences. He has been involved in over 25 venture capital financings including recent investments in Galapagos (GLPG), SCYNEXIS, Catalyst Biosciences, Pharmasset (VRUS), Neurotech Pharmaceuticals, Logical Therapeutics, TRF Pharma, and Nora Pharmaceuticals. Fong currently serves on the boards of directors for Neurotech Pharmaceuticals, Odyssey Thera, TRF Pharma, Nora Pharmaceuticals, and Logical Therapeutics (observer).

Prior to joining Burrill & Company, Fong held positions as a biochemist and molecular biologist with two early stage biotechnology companies located in the San Francisco Bay Area. Mr. Fong's aggregate research experiences include recombinant protein expression in yeast, development of linear artificial chromosomes, and catalytic RNA technology. Fong earned his bachelors degree with distinction and honors in Molecular and Cell Biology- Biochemistry from the University of California, Berkeley.

Dr. Matthew J. Plunkett
Vice President and Chief Financial Officer

Matthew J. Plunkett is vice president and chief financial officer at iPierian. Prior to joining the company, Dr. Plunkett spent nine years at Oppenheimer & Co., most recently as Managing Director where he lead the firm's biotechnology investment banking practice for the West Coast. His investment banking experience includes over 60 completed biopharmaceutical transactions, including initial public offerings, follow-on offerings, convertible debt, private placements, and M&A and other financial advisory assignments. Previously, he worked as a research scientist at Sunesis Pharmaceuticals and at Axys Advanced Technologies. He received a Ph.D. in Organic Chemistry from the University of California, Berkeley, where he worked in the lab of Dr. Jonathan Ellman to develop synthetic methodology for the synthesis of structurally diverse small-molecule combinatorial libraries for drug discovery and lead optimization. He received a B.S. with honors in Chemistry, with a History concentration, from Harvey Mudd College.

Peter R. Scott
Head of Life Sciences, SVB Silicon Valley Bank

Pete Scott is currently the Head of Life Sciences for the Bank's Life Science Practice on the West Coast. These responsibilities include management and leadership of the Bank's Life Science effort including the development of new relationships with life science companies headquartered on the West Coast, developing and expanding relationships with the life science venture capital community on the West Coast, and contributing to SVB's status as a thought leader within the Life Science community. Mr. Scott has

historically held various senior positions at Silicon Valley Bank including Senior Vice President and Manager of the Life Sciences Team, Communications & Electronics Team, and Semiconductor Team. Over Mr. Scott's twelve-year tenure with Silicon Valley Bank, he has worked with a wide range of high tech and life science companies including those in the biotechnology, medical devices, semiconductor, and telecommunications industries. Prior to joining Silicon Valley Bank, Mr. Scott spent six years as a senior lender in the Commercial Lending Division of Wells Fargo Bank. Mr. Scott received his B.S in Business Administration from Northern Illinois University in 1989.